首页> 美国卫生研究院文献>Cancer Management and Research >Gastrointestinal Stromal Tumors of the Small Intestine: Progress in Diagnosis and Treatment Research
【2h】

Gastrointestinal Stromal Tumors of the Small Intestine: Progress in Diagnosis and Treatment Research

机译:小肠的胃肠道基质肿瘤:诊断和治疗研究进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In recent years, the diagnosis and treatment of gastrointestinal stromal tumors (GISTs) of the small intestine have been a hot topic due to their rarity and non-specific clinical manifestations. With the development of gene and imaging technology, surgery, and molecular targeted drugs, the diagnosis and treatment of GISTs have achieved great success. For a long time, radical resection was prioritized to treat GISTs of the small intestine. At present, preoperative tumor staging is a novel treatment for unresectable malignant tumors. In addition, karyokinesis exponent is the sole independent predictor of progression-free survival of GISTs. The DNA, miRNA, and protein of exosomes have also been found to be biomarkers with prognostic implications. The research on the treatment of GISTs has become a focus in the era of precision medicine, ushering in the use of standardized, normalized, and individualized treatment.
机译:近年来,由于其罕见和非特异性临床表现,小肠的胃肠道间质瘤(GIST)的胃肠道肿瘤(GIST)是一种热门话题。随着基因和成像技术,手术和分子靶向药物的发展,GISTS的诊断和治疗取得了巨大的成功。很长一段时间,优先考虑激进切除,以治疗小肠的GIST。目前,术前肿瘤分期是对不可切除的恶性肿瘤的新方法。此外,Karyokinesis指数是Gists的无进展生存的唯一独立预测因子。还发现外泌体的DNA,miRNA和蛋白质是具有预后意义的生物标志物。对GISTS治疗的研究已成为精密药物时代的重点,迎来使用标准化,标准化和个性化治疗。

著录项

  • 期刊名称 Cancer Management and Research
  • 作者

    Fangxing Peng; Yao Liu;

  • 作者单位
  • 年(卷),期 2020(-1),-1
  • 年度 2020
  • 页码 -1
  • 总页数 13
  • 原文格式 PDF
  • 正文语种
  • 中图分类 肿瘤学;
  • 关键词

    机译:胃肠道质量肿瘤;GIST;小肠;新建治疗;术前肿瘤分期;Karyokinesis指数;外来;

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号